Identification of Molecular Subtypes in TME

The molecular subtypes in the tumor microenvironment (TME) are typically defined based on the expression patterns of specific genes or proteins within the tumor and its surrounding environment. It has been employed in the TME to shed light on the intricate interplay between tumor and host, and to inform implications for cancer therapy. At Alfa Cytology, we are dedicated to deepening our comprehension of tumor biology in this field.

Molecular Subtypes in TME

The molecular subtypes have distinct roles and impacts on tumor biology. In the context of immune cells, molecular subtyping of the TME can identify distinct immune cell populations and their functional states. This information can be used to classify tumors into subtypes characterized by different immune infiltration patterns, such as "hot" tumors with abundant immune cell infiltration or "cold" tumors with limited immune cell presence. Understanding these subtypes can help guide the selection of immunotherapies, such as immune checkpoint inhibitors, which may be more effective in certain TME subtypes. By identifying distinct molecular subtypes within the TME, researchers and clinicians can tailor treatment strategies, predict response to therapy, and develop novel therapeutic approaches to improve patient outcomes.

Fig. 1 Molecular subtyping of cancer workflow. (Zhao L, et al, 2019)

Identification of Molecular Subtypes in TME

At Alfa Cytology, we specialize in the identification of molecular subtypes in the TME, offering comprehensive services to unravel the intricate interplay between tumor cells and the immune system. Our services include, but are not limited to:

• Molecular Subtype Characterization in TME

Through genomic profiling techniques, such as next-generation sequencing (NGS), we are able to comprehensively characterize the molecular subtypes within the TME. Then we can assist our clients in identifying specific genomic alterations associated with different subtypes, thereby enhancing the understanding of tumor heterogeneity, and helping determine the prognosis, treatment response, and potential therapeutic targets for individual patients.

• Decoding Epigenetic Subtypes in TME

We employ epigenomic profiling techniques, such as DNA methylation analysis, to identify distinct epigenetic subtypes across various cancer types. Then we are able to discover specific epigenetic patterns associated with different tumor subtypes. By integrating epigenomic data with other molecular profiling data, we can provide valuable insights into their biological characteristics and potential therapeutic targets.

• Unraveling Gene Expression Patterns for Targeted Therapies

By employing techniques such as RNA sequencing, we can quantify gene expression patterns and identify differentially expressed genes associated with specific molecular subtypes in the TME. Consequently, we can provide invaluable assistance to our clients in elucidating the pathways implicated in tumor progression, immune response, as well as identifying novel biomarkers and therapeutic targets.

• Integration of Multi-Omics Data

We integrate data from various omics platforms, including genomics, epigenomics, transcriptomics, and proteomics. By combining multiple layers of molecular information, we can provide a comprehensive understanding of the TME, uncovering intricate interactions and contributing to identifying potential therapeutic targets.

At Alfa Cytology, we employ a comprehensive approach by integrating data from multiple omics platforms, including genomics, epigenomics, transcriptomics, and proteomics. By combining these diverse layers of molecular information, we gain a holistic understanding of the TME, thereby supporting our clients in unraveling intricate interactions and identifying potential therapeutic targets. Contact us today to learn more about how our services can benefit your research.

Reference

1. Zhao L, et al. Molecular subtyping of cancer: current status and moving toward clinical applications. Brief Bioinform, 2019;20(2):572-584.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.